Gene and Cell Therapy Stocks Scatter Chart

18 companies Industry in Healthcare P/E vs Revenue Growth (1y) (TTM)
Universe
Plot any two of 343 metrics The preset pairs are free. Subscribers can put any metric on either axis.
Highlight

P/E vs Revenue Growth (1y) (TTM)

Company Outlier, pinned to the edge Highlighted Trend

Each dot is one of the 18 Gene and Cell Therapy stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 25.3% and the median P/E 22.17. Pinned to the edge: 3 outliers on X and 0 on Y.

Rank correlation -0.10 Trend R² 0.04 X middle half 8.4% to 130.6% Y middle half 7.90 to 38.87
4High Revenue Growth (1y) (TTM), high P/E
5Low Revenue Growth (1y) (TTM), high P/E
4Low Revenue Growth (1y) (TTM), low P/E
5High Revenue Growth (1y) (TTM), low P/E

Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.

Companies

18 plotted
# Industry
1 JNJJohnson & Johnson 7.8% 42.48 $683.70B Pharmaceuticals
2 AZNAstrazeneca 7.8% 25.93 $286.04B Pharmaceuticals
3 VRTXVertex Pharmaceuticals 10.5% 34.21 $136.01B Biotechnology
4 BMYBristol Myers Squibb 4.2% 13.94 $128.87B Pharmaceuticals
5 UTHRUnited Therapeutics 1.9% 20.35 $25.04B Pharmaceuticals
6 NBIXNeurocrine Biosciences 38.0% 24.00 $16.86B Pharmaceuticals
7 TGTXTg Therapeutics 68.8% 83.08 $8.81B Biotechnology
8 KRYSKrystal Biotech 26.0% 38.98 $8.78B Gene and Cell Therapy
9 VCELVericel 25.3% 88.66 $2.95B Gene and Cell Therapy
10 LKFTLakefront Biotherapeutics 240.8% 2.46 $2.29B Biotechnology
11 PGENPrecigen 2,388%OUT 63.63 $1.55B Gene and Cell Therapy
12 PCRXPacira BioSciences 3.7% 38.55 $1.45B Pharmaceuticals
13 MGTXMeiraGTx Holdings 1,366%OUT 10.92 $854.96M Gene and Cell Therapy
14 AGENAgenus 25.4% 13.46 $396.56M Biotechnology
15 ALECAlector 151.2% 6.89 $285.25M Biotechnology
16 FBIOFortress Biotech 12.3% 0.59 $54.36M Biotechnology
17 ATNMActinium Pharmaceuticals 936.3%OUT 4.12 $46.63M Biotechnology
18 PLURPluri 10.0% 0.00 $12.66M Gene and Cell Therapy

Frequently Asked Questions

Which Gene and Cell Therapy stocks look cheap relative to their growth?

Among Gene and Cell Therapy stocks, the largest companies growing revenue faster than the median (25.3%) while trading below the median P/E (22.17) are Lakefront Biotherapeutics (LKFT), MeiraGTx Holdings (MGTX), Agenus (AGEN), Alector (ALEC) and Actinium Pharmaceuticals (ATNM). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.

Which Gene and Cell Therapy stocks are expensive for their growth?

The largest companies with a P/E above the median and revenue growth below it are Johnson & Johnson (JNJ), Astrazeneca (AZN), Vertex Pharmaceuticals (VRTX), Vericel (VCEL) and Pacira BioSciences (PCRX).

What is the median P/E of Gene and Cell Therapy stocks?

The median P/E across the 18 Gene and Cell Therapy stocks plotted is 22.17, with the middle half between 7.90 and 38.87.

What is the median Revenue Growth (1y) (TTM) of Gene and Cell Therapy stocks?

The median is 25.3%, with the middle half between 8.4% and 130.6%.

Is there a relationship between Revenue Growth (1y) (TTM) and P/E for Gene and Cell Therapy stocks?

The rank correlation (Spearman) is -0.10, a weak negative relationship: companies with a higher Revenue Growth (1y) (TTM) tend to have a lower P/E.

How does this chart handle outliers?

A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 3 companies are outliers on Revenue Growth (1y) (TTM) and 0 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.

Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry is included unless you choose primary industry only. Nothing on this page is investment advice.